Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shuang-Huang-Lian oral solution for COVID-19 pneumonia
ChiCTR2000029605Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Feb 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of shuanghuanglian in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia (4 arms), sponsored by Tongji Hospital. Primary endpoint: Time to disease recovery. Started Feb 2020; status: recruiting.
02
Drugs
shuanghuanglian
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on ChiCTR2000029605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029605.